503A Tirzepatide Rules
Patient-specific compounding, and its limits.
Released: · Last reviewed:
Patient-specific compounding, and its limits.
Across the 15 programs we can price at 10 mg, all-in cost runs from $129 to $399 a month, month to month (read October 15, 2026; NexLife as of November 6, 2026). Every figure on this page is on that same all-in basis.
All-in monthly cost = medication plus any mandatory recurring fee, at a named dose, month to month, before tax and before prepaid discounts. Competitor prices read October 15, 2026; NexLife’s as of November 6, 2026. How we verify a price.
How to verify this yourself
Regulatory summaries age badly, this one included. FDA's drug compounding pages, its shortage database and its published warning letters are the primary sources, all free and searchable by company name. If this page and the agency disagree, the agency is right and telling us is the fastest way to fix it for everyone.
Proposal, enforcement, or rule
Three different things that coverage routinely conflates. A proposed exclusion from a bulks list is not a rule. A warning letter is about claims rather than a finding of patient harm. Only a final rule changes what is lawful. If a regulatory story is being used to sell you something urgently, the urgency is the marketing.
What it changes for a patient
Rarely the prescription requirement, the pharmacy licensing framework or the clinical review. Usually price, which programmes operate, and what may lawfully be compounded at scale. Do not let supply run to zero, keep your prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
Proposal, enforcement, or final rule
Three different things that coverage routinely conflates. A proposed exclusion from a bulks list is not a rule. A warning letter is a formal statement that specific claims are unlawful, not a finding of patient harm. Only a final rule changes what may lawfully be done.
If a regulatory story is being used to sell you something urgently, the urgency is the marketing. Nothing in this category has ever required a same-day decision from a patient.
How to verify any of this yourself
FDA's drug compounding pages, its shortage database and its published warning letters are the primary sources, all free and searchable by company name. State boards publish their own actions. If this page and the agency disagree, the agency is right and telling us is the fastest way to fix it for everyone.
What regulatory change does and does not touch
It rarely changes the prescription requirement, the pharmacy licensing framework or the clinical review. It routinely changes price, which programmes operate, and what may be compounded at scale. Several large platforms left the compounded market during 2026 for exactly these reasons.
The practical defences are boring: do not let supply run to zero, keep your prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
How this connects to what you will actually pay
Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 15 programs we can price at 10 mg, that runs from $129 to $399 a month all-in, about three times as much at the top as at the bottom, for compounded tirzepatide from the same category of licensed pharmacy.
One of those 15 programs charges a recurring program fee on top of medication, and 10 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.
What we could verify and what we could not
15 of the 32 programs we track have a month-to-month 10 mg price we read on the program’s own site (October 15, 2026; NexLife as of November 6, 2026). The rest print no comparable price, blocked our reader or sell brand Zepbound only, and we show no third-party figure for them. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.
Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.
The regulatory distinction that sits under all of this
Compounded tirzepatide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. Compounded tirzepatide is made with the drug in Zepbound but is not the same product, and FDA does not review it before sale; the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.
That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.
How to check this against the primary record
Regulatory summaries age badly, this one included. FDA publishes its compounding pages, its shortage database and its warning letters, all free and searchable by company name. Where this page and the agency disagree, the agency is right.
Three things get conflated in coverage of this area: a proposal, an enforcement action and a final rule. Only the third changes what is lawful.
What it changes for someone paying cash
Rarely the prescription requirement, the licensing framework or the clinical review. Usually price, which programmes operate, and what may lawfully be compounded at scale. Five large programmes stopped selling compounded tirzepatide during 2026 and patients generally found out at renewal.
The practical response is unglamorous: do not let supply run to zero, keep a prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
Why regulatory news is used as a sales tool
Because urgency sells. A programme citing a rule change to push you into a twelve-month prepayment is using a genuine regulatory fact to manufacture a deadline that does not apply to you. Read the rule, not the email about the rule.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.